OpenLB
Open Library of Bioscience
Advanced Search
Bioengineering (Basel, Switzerland)
Jun 25, 2023;10 (7):

Recent Advances in Nanomaterials-Based Targeted Drug Delivery for Preclinical Cancer Diagnosis and Therapeutics.

Harshita Tiwari, Nilesh Rai, Swati Singh, Priyamvada Gupta, Ashish Verma, Akhilesh Kumar Singh, Prafull Salvi, Santosh Kumar Singh, Vibhav Gautam
Author Information
  1. Harshita Tiwari: Centre of Experimental Medicine and Surgery, Institute of Medical Sciences, Banaras Hindu University, Varanasi 221005, India.
  2. Nilesh Rai: Centre of Experimental Medicine and Surgery, Institute of Medical Sciences, Banaras Hindu University, Varanasi 221005, India. ORCID
  3. Swati Singh: Centre of Experimental Medicine and Surgery, Institute of Medical Sciences, Banaras Hindu University, Varanasi 221005, India.
  4. Priyamvada Gupta: Centre of Experimental Medicine and Surgery, Institute of Medical Sciences, Banaras Hindu University, Varanasi 221005, India.
  5. Ashish Verma: Centre of Experimental Medicine and Surgery, Institute of Medical Sciences, Banaras Hindu University, Varanasi 221005, India.
  6. Akhilesh Kumar Singh: Department of Oral and Maxillofacial Surgery, Faculty of Dental Sciences, Institute of Medical Sciences, Banaras Hindu University, Varanasi 221005, India.
  7. Kajal: Department of Agriculture Biotechnology, National Agri-Food Biotechnology Institute, Sahibzada Ajit Singh Nagar 140306, India.
  8. Prafull Salvi: Department of Agriculture Biotechnology, National Agri-Food Biotechnology Institute, Sahibzada Ajit Singh Nagar 140306, India. ORCID
  9. Santosh Kumar Singh: Centre of Experimental Medicine and Surgery, Institute of Medical Sciences, Banaras Hindu University, Varanasi 221005, India. ORCID
  10. Vibhav Gautam: Centre of Experimental Medicine and Surgery, Institute of Medical Sciences, Banaras Hindu University, Varanasi 221005, India. ORCID
PMID: 37508788 DOI: 10.3390/bioengineering10070760

Abstract

Nano-oncology is a branch of biomedical research and engineering that focuses on using nanotechnology in cancer diagnosis and treatment. Nanomaterials are extensively employed in the field of oncology because of their minute size and ultra-specificity. A wide range of nanocarriers, such as dendrimers, micelles, PEGylated liposomes, and polymeric nanoparticles are used to facilitate the efficient transport of anti-cancer drugs at the target tumor site. Real-time labeling and monitoring of cancer cells using quantum dots is essential for determining the level of therapy needed for treatment. The drug is targeted to the tumor site either by passive or active means. Passive targeting makes use of the tumor microenvironment and enhanced permeability and retention effect, while active targeting involves the use of ligand-coated nanoparticles. Nanotechnology is being used to diagnose the early stage of cancer by detecting cancer-specific biomarkers using tumor imaging. The implication of nanotechnology in cancer therapy employs photoinduced nanosensitizers, reverse multidrug resistance, and enabling efficient delivery of CRISPR/Cas9 and RNA molecules for therapeutic applications. However, despite recent advancements in nano-oncology, there is a need to delve deeper into the domain of designing and applying nanoparticles for improved cancer diagnostics.

Keywords

biomarker cancer drug resistance nanoformulation nanoimaging nanotechnology

References

  1. J Am Chem Soc. 2023 Apr 12;145(14):8130-8140 [PMID: 37001012]
  2. Egypt J Immunol. 2022 Jul;29(3):54-63 [PMID: 35758969]
  3. Adv Healthc Mater. 2022 Jun;11(12):e2200163 [PMID: 35184421]
  4. J Magn Reson Imaging. 2006 Jul;24(1):123-31 [PMID: 16755542]
  5. J Mater Chem B. 2023 Jan 18;11(3):648-656 [PMID: 36541124]
  6. Biomed Pharmacother. 2022 Aug;152:113250 [PMID: 35700679]
  7. Biomedicines. 2022 Feb 24;10(3): [PMID: 35327333]
  8. Drug Discov Today. 2020 Jan;25(1):160-167 [PMID: 31614201]
  9. Nanoscale Adv. 2023 May 1;5(11):3044-3052 [PMID: 37260505]
  10. Eur J Surg Oncol. 2022 Jan;48(1):44-52 [PMID: 34548216]
  11. Mol Cancer Ther. 2020 Feb;19(2):564-574 [PMID: 31645443]
  12. Nanomedicine. 2022 Nov;46:102598 [PMID: 36089234]
  13. Biomater Sci. 2023 May 16;11(10):3394-3413 [PMID: 36847174]
  14. Drug Resist Updat. 2022 Jul;63:100844 [PMID: 35533630]
  15. Nanoscale Res Lett. 2021 Dec 5;16(1):173 [PMID: 34866166]
  16. Colloids Surf B Biointerfaces. 2022 May;213:112422 [PMID: 35231688]
  17. Biomed Pharmacother. 2022 Jun;150:112995 [PMID: 35658243]
  18. Int J Mol Sci. 2022 Nov 09;23(22): [PMID: 36430279]
  19. Front Mol Biosci. 2020 Aug 20;7:193 [PMID: 32974385]
  20. Eur J Pharm Sci. 2010 Jan 31;39(1-3):152-63 [PMID: 19961929]
  21. Theranostics. 2022 Jan 31;12(5):1999-2014 [PMID: 35265195]
  22. Cancers (Basel). 2022 Dec 06;14(23): [PMID: 36497498]
  23. Genes Dis. 2022 Aug 05;10(3):1005-1018 [PMID: 37396515]
  24. Pharm Dev Technol. 2022 Mar;27(3):357-371 [PMID: 35350969]
  25. Expert Opin Drug Deliv. 2022 Feb;19(2):147-161 [PMID: 35130795]
  26. J Control Release. 2022 Oct;350:584-599 [PMID: 36037975]
  27. Prostaglandins Other Lipid Mediat. 2020 Feb;146:106402 [PMID: 31841664]
  28. Med Res Rev. 2024 Jan;44(1):138-168 [PMID: 37294298]
  29. Acta Biomater. 2022 May;144:109-120 [PMID: 35314366]
  30. Cancer Cell Int. 2022 Sep 25;22(1):293 [PMID: 36154921]
  31. Bioorg Med Chem. 2020 Jan 15;28(2):115235 [PMID: 31843464]
  32. J Pharm Pharmacol. 2002 Dec;54(12):1573-600 [PMID: 12542887]
  33. J Drug Target. 2022 Sep;30(8):801-818 [PMID: 35465812]
  34. Drug Discov Today. 2020 Jun;25(6):997-1012 [PMID: 32334073]
  35. Biosci Biotechnol Biochem. 2019 May;83(5):869-875 [PMID: 30700211]
  36. J Med Chem. 2022 Apr 14;65(7):5850-5865 [PMID: 35380045]
  37. Bioeng Transl Med. 2023 Feb 08;8(3):e10486 [PMID: 37206223]
  38. Biomed Pharmacother. 2023 Jan;157:114065 [PMID: 36481408]
  39. Int J Pharm. 2021 Mar 15;597:120346 [PMID: 33545283]
  40. Int J Mol Sci. 2022 Dec 30;24(1): [PMID: 36614128]
  41. Breast Cancer Res. 2022 May 23;24(1):35 [PMID: 35606863]
  42. Biochim Biophys Acta Rev Cancer. 2021 Apr;1875(2):188503 [PMID: 33421585]
  43. Mol Cancer. 2022 Apr 27;21(1):105 [PMID: 35477447]
  44. Biomaterials. 2020 Oct;255:120210 [PMID: 32592871]
  45. Mater Sci Eng C Mater Biol Appl. 2017 Nov 1;80:59-68 [PMID: 28866205]
  46. Adv Mater. 2023 Mar;35(10):e2207342 [PMID: 36524460]
  47. Nanoscale. 2022 Jul 28;14(29):10399-10417 [PMID: 35819245]
  48. Int J Nanomedicine. 2011;6:2679-88 [PMID: 22114498]
  49. J Magn Reson Imaging. 2023 Oct;58(4):1177-1188 [PMID: 36773005]
  50. J Pharm Biomed Anal. 2023 Feb 20;225:115206 [PMID: 36586382]
  51. Ultrason Sonochem. 2020 Oct;67:105188 [PMID: 32473543]
  52. Front Pharmacol. 2018 Feb 09;8:1002 [PMID: 29479316]
  53. Appl Biochem Biotechnol. 2022 Jul;194(7):3296-3319 [PMID: 35349089]
  54. ACS Chem Biol. 2021 Nov 19;16(11):2068-2086 [PMID: 34724607]
  55. J Fungi (Basel). 2022 Mar 10;8(3): [PMID: 35330287]
  56. Cell Oncol (Dordr). 2021 Aug;44(4):715-737 [PMID: 33835425]
  57. J Nanobiotechnology. 2015 Oct 01;13:63 [PMID: 26427800]
  58. J Physiol Pharmacol. 2022 Jun;73(3): [PMID: 36515626]
  59. Bioconjug Chem. 2023 Jan 18;34(1):248-256 [PMID: 36621834]
  60. J Clin Med. 2022 Mar 10;11(6): [PMID: 35329850]
  61. Brain Res. 2022 Apr 15;1781:147786 [PMID: 35041841]
  62. ACS Appl Bio Mater. 2021 Feb 15;4(2):1140-1155 [PMID: 35014471]
  63. Int J Mol Sci. 2022 Mar 25;23(7): [PMID: 35408970]
  64. Int J Biol Macromol. 2022 Dec 1;222(Pt B):2309-2317 [PMID: 36228812]
  65. Nat Commun. 2022 Jan 11;13(1):256 [PMID: 35017504]
  66. Biomedicines. 2021 Oct 14;9(10): [PMID: 34680593]
  67. Acta Biomater. 2022 Jul 15;147:299-313 [PMID: 35640802]
  68. Int J Nanomedicine. 2020 Jul 31;15:5459-5471 [PMID: 32801700]
  69. Nanomedicine. 2023 Jan;47:102620 [PMID: 36265559]
  70. J Mater Chem B. 2021 Jan 7;9(1):9-22 [PMID: 33179710]
  71. Biomaterials. 2023 Apr;295:122056 [PMID: 36805243]
  72. Colloids Surf B Biointerfaces. 2015 Sep 1;133:254-62 [PMID: 26117805]
  73. Front Pharmacol. 2022 Feb 14;13:776895 [PMID: 35237155]
  74. J Control Release. 2020 Apr 10;320:45-62 [PMID: 31923537]
  75. Acta Biomater. 2020 Jun;109:21-36 [PMID: 32294554]
  76. Chem Commun (Camb). 2021 Jul 20;57(58):7067-7082 [PMID: 34195709]
  77. Int J Pharm. 2022 Mar 5;615:121509 [PMID: 35085734]
  78. Int J Mol Sci. 2022 Jul 13;23(14): [PMID: 35887063]
  79. Langmuir. 2020 Jan 14;36(1):388-396 [PMID: 31826617]
  80. Int J Pharm. 2022 Jun 25;622:121860 [PMID: 35654378]
  81. Int J Mol Sci. 2022 Jul 17;23(14): [PMID: 35887226]
  82. ACS Nano. 2022 Aug 23;16(8):12226-12243 [PMID: 35968931]
  83. Int J Biol Macromol. 2023 Feb 15;228:273-285 [PMID: 36581023]
  84. Biomaterials. 2012 Jul;33(20):5107-14 [PMID: 22494888]
  85. Sci Rep. 2019 Jun 19;9(1):8777 [PMID: 31217534]
  86. J Oncol Pharm Pract. 2022 Jun;28(4):1003-1008 [PMID: 35037777]
  87. J Colloid Interface Sci. 2023 Jun 15;640:41-51 [PMID: 36827847]
  88. Proc Natl Acad Sci U S A. 2022 Aug 23;119(34):e2207841119 [PMID: 35969778]
  89. Front Bioeng Biotechnol. 2020 Jun 16;8:631 [PMID: 32612988]
  90. Biosens Bioelectron. 2019 Apr 1;130:147-165 [PMID: 30735948]
  91. Langmuir. 2023 Apr 4;39(13):4766-4776 [PMID: 36939641]
  92. Acta Pharm Sin B. 2023 Apr;13(4):1429-1437 [PMID: 37139433]
  93. Immunotherapy. 2022 Apr 28;: [PMID: 35481350]
  94. Mycology. 2021 Jan 27;12(3):139-159 [PMID: 34552808]
  95. RSC Adv. 2023 Mar 14;13(13):8606-8629 [PMID: 36926304]
  96. Nanomedicine. 2012 Oct;8(7):1096-105 [PMID: 22349096]
  97. Anal Methods. 2022 May 27;14(20):1938-1945 [PMID: 35441184]
  98. Genes Dis. 2023 Jan 14;11(1):189-204 [PMID: 37588236]
  99. Front Oncol. 2021 Oct 22;11:749970 [PMID: 34745974]
  100. Clin Exp Metastasis. 2022 Oct;39(5):833-840 [PMID: 35819644]
  101. Nanomedicine. 2022 Feb;40:102477 [PMID: 34740868]
  102. Anal Chim Acta. 2019 Sep 13;1071:59-69 [PMID: 31128756]
  103. Int J Cancer. 2010 Apr 1;126(7):1683-90 [PMID: 19795454]
  104. Int J Nanomedicine. 2023 Feb 17;18:861-879 [PMID: 36844433]
  105. Ecotoxicol Environ Saf. 2021 Aug 16;224:112626 [PMID: 34411822]
  106. Bioorg Chem. 2020 Jun;99:103802 [PMID: 32330735]
  107. Pharmaceutics. 2023 Feb 02;15(2): [PMID: 36839827]
  108. Pathol Res Pract. 2023 Mar;243:154363 [PMID: 36764011]
  109. J Control Release. 2021 Feb 10;330:1046-1070 [PMID: 33188829]
  110. Carcinogenesis. 2020 Jul 10;41(5):582-590 [PMID: 31740975]
  111. Drug Deliv Transl Res. 2020 Aug;10(4):1147-1169 [PMID: 32410157]
  112. Acta Pharm Sin B. 2022 May;12(5):2533-2549 [PMID: 35646521]
  113. Br J Cancer. 2013 May 28;108(10):2021-32 [PMID: 23632475]
  114. Carbohydr Polym. 2020 Dec 1;249:116837 [PMID: 32933681]
  115. Macromol Biosci. 2022 Aug;22(8):e2200130 [PMID: 35579182]
  116. ACS Omega. 2023 Jan 20;8(4):3768-3784 [PMID: 36743019]
  117. Nanomedicine. 2018 Aug;14(6):1949-1961 [PMID: 29045824]
  118. Drug Deliv. 2022 Dec;29(1):2959-2970 [PMID: 36085575]
  119. Cancer Chemother Pharmacol. 2021 Nov;88(5):771-793 [PMID: 34510251]
  120. Adv Healthc Mater. 2020 Jan;9(2):e1901307 [PMID: 31814332]
  121. Pharmaceutics. 2022 Jun 23;14(7): [PMID: 35890220]
  122. Biofactors. 2023 May-Jun;49(3):663-683 [PMID: 36744732]
  123. Mol Ther Methods Clin Dev. 2022 Mar 16;25:158-169 [PMID: 35402634]
  124. Prog Mol Biol Transl Sci. 2019;162:229-239 [PMID: 30905452]
  125. Cell Death Dis. 2022 Oct 28;13(10):909 [PMID: 36307400]
  126. Chem Rev. 2015 Oct 14;115(19):10530-74 [PMID: 26313138]
  127. Eur J Med Chem. 2022 Sep 5;239:114542 [PMID: 35751979]
  128. J Pharm Sci. 2021 Apr;110(4):1788-1798 [PMID: 33529684]
  129. Nano Converg. 2019 Jul 15;6(1):23 [PMID: 31304563]
  130. Int J Nanomedicine. 2015 Jun 11;10:3937-53 [PMID: 26185437]
  131. J Exp Clin Cancer Res. 2022 Aug 19;41(1):252 [PMID: 35986402]
  132. Macromol Biosci. 2016 Mar;16(3):420-31 [PMID: 26647779]
  133. Mol Biol Rep. 2023 Apr;50(4):3023-3033 [PMID: 36662452]
  134. Pharmaceutics. 2021 Aug 11;13(8): [PMID: 34452196]
  135. Int J Nanomedicine. 2021 Feb 17;16:1313-1330 [PMID: 33628022]
  136. Sci Rep. 2020 Mar 2;10(1):3800 [PMID: 32123231]
  137. Front Chem. 2021 May 28;9:688442 [PMID: 34124008]
  138. J Control Release. 2022 Oct;350:350-359 [PMID: 35988780]
  139. ACS Appl Nano Mater. 2022 Sep 23;5(9):12506-12517 [PMID: 36185166]
  140. ACS Omega. 2022 Dec 07;7(50):46653-46673 [PMID: 36570288]
  141. Bioact Mater. 2023 Feb 04;25:189-200 [PMID: 36817822]
  142. Signal Transduct Target Ther. 2021 Nov 22;6(1):404 [PMID: 34803167]
  143. Cancer Metastasis Rev. 2019 Sep;38(3):333-346 [PMID: 31659564]
  144. Int J Nanomedicine. 2014 Aug 22;9:4055-66 [PMID: 25187709]
  145. PLoS One. 2022 Mar 17;17(3):e0264673 [PMID: 35298472]
  146. Small Methods. 2023 May;7(5):e2201307 [PMID: 36604976]
  147. Crit Rev Oncol Hematol. 2023 May;185:103961 [PMID: 36921781]
  148. Pharmaceutics. 2023 Jan 08;15(1): [PMID: 36678845]
  149. Spectrochim Acta A Mol Biomol Spectrosc. 2021 Feb 15;247:119038 [PMID: 33120124]
  150. Colloids Surf B Biointerfaces. 2021 Jun;202:111673 [PMID: 33714186]

Grants

  1. EEQ/2019/000025/Science and Engineering Research Board
  2. F.30-504/2020 (BSR)/University Grants Commission
  3. N/A/Banaras Hindu University
Journal Article Review
Article has an altmetric score of 4

Word Cloud

Created with Highcharts 10.0.0cancertumorusingnanotechnologynanoparticlestreatmentusedefficientsitetherapydrugactivetargetinguseresistanceNano-oncologybranchbiomedicalresearchengineeringfocusesdiagnosisNanomaterialsextensivelyemployedfieldoncologyminutesizeultra-specificitywiderangenanocarriersdendrimersmicellesPEGylatedliposomespolymericfacilitatetransportanti-cancerdrugstargetReal-timelabelingmonitoringcellsquantumdotsessentialdetermininglevelneededtargetedeitherpassivemeansPassivemakesmicroenvironmentenhancedpermeabilityretentioneffectinvolvesligand-coatedNanotechnologydiagnoseearlystagedetectingcancer-specificbiomarkersimagingimplicationemploysphotoinducednanosensitizersreversemultidrugenablingdeliveryCRISPR/Cas9RNAmoleculestherapeuticapplicationsHoweverdespiterecentadvancementsnano-oncologyneeddelvedeeperdomaindesigningapplyingimproveddiagnosticsRecentAdvancesNanomaterials-BasedTargetedDrugDeliveryPreclinicalCancerDiagnosisTherapeuticsbiomarkernanoformulationnanoimaging

Similar Articles

Cited By